Advanced in vitro models, such as our liver fibrosis model, are known to provide a more efficient and cost-effective way to screen potential drug candidates, accelerating the drug discovery process. In vitro models are cell culture models are used to screen potential drug candidates and evaluate their efficacy and safety before moving on to animal and human trials. These models have become increasingly popular in recent years, due to their ability to reduce the cost and time associated with drug discovery and development.

3D Cell Culture Liver Fibrosis Model

Our liver fibrosis assay uses 3D cell culture models that incorporate a mixture of hepatocytes or hepatocyte-like cells with nonparenchymal cells (NPCs) to provide the greatest utility. This method provides a more accurate representation of the in vivo environment and allows for the evaluation of multiple genes at once. The assay analyzes gene expression via qPCR, allowing for many genes of interest to be evaluated using a single sample.

3D cell culture models offer several benefits in drug discovery, including better mimicking of the in vivo microenvironment and gene expression of tissues, providing a method for improving in vitro studies used in drug discovery and development. They also allow for the evaluation of multiple genes at once and can be customized to meet specific research requirements. Nonparenchymal cells are incorporated into 3D cell culture models to better mimic the in vivo microenvironment and gene expression of tissues. This is important because it provides a more accurate representation of the in vivo environment and allows for more accurate evaluation of drug candidates.

qPCR Analysis

qPCR is a method used to analyze gene expression in 3D cell culture models. It allows for the evaluation of multiple genes at once using a single sample, providing a more efficient and cost-effective method for evaluating drug candidates. Our liver fibrosis assay uses qPCR to analyze gene expression, providing researchers with a more comprehensive understanding of the effects of potential drug candidates.

Why Work With Us?

Our quality control process in place for all new cell and control compound lots to ensure standardization of their liver assays. We also validate our assays using multiple methods to ensure accuracy and reliability. This ensures consistent and reliable results, providing researchers with the confidence they need to move forward with drug discovery and development.

Advanced in vitro models contribute to the efficiency and cost-effectiveness of drug discovery by providing a more accurate representation of the in vivo environment, allowing for the evaluation of multiple genes at once, and reducing the need for animal and human trials. There are several examples of drugs that have been discovered using advanced in vitro models, including drugs for cancer, liver disease, and other conditions.

Advanced in vitro models provide a more efficient and cost-effective way to screen potential drug candidates, accelerating the drug discovery process. These models offer several benefits, including better mimicking of the in vivo microenvironment and gene expression of tissues, providing a method for improving in vitro studies used in drug discovery and development. Our liver fibrosis assay provides researchers with consistent and reliable results, ensuring the confidence needed to move forward with drug discovery and development. To learn more about this assay, reach out to a member of our team to get started today!

Drug discovery and development is a complex process that involves identifying potential drug candidates, testing them in vitro and in vivo, and finally obtaining regulatory approval for clinical use. The process is time-consuming, expensive, and often fails due to poor efficacy or toxicity. One of the main challenges with the drug discovery paradigm has always been the poor translational gap between inexpensive in vitro studies and significantly costly in vivo studies. Traditionally, cell culture models have been inadequate in recapitulating the complex in vivo microenvironment and thus have been limited in their ability to predict in vivo efficacy and toxicity. While no model is perfect, in vivo animal studies do not well-translate to results obtained in human clinical trials, particularly with regard to toxicology.

In Vitro Antibody Pharmacokinetics Assay

One of the services we offer is our In Vitro Antibody Pharmacokinetics Assay, which measures the distribution of biologicals, including antibody drugs, into solid tumor models. The assay utilizes tumor spheroid models and high content confocal imaging to assess the distance and quantity of antibody penetration into tumor spheroids. The assay can screen the relative differences in distribution of various biologicals, including antibody drug conjugates, antibody fragments, alternate domain antibodies, affibodies, and nanobodies. The assay can measure distribution curves, velocity curves, TD50 values, and concentration-time curves. The assay offers a cost-effective and time-saving alternative to animal studies for drug development.

3D Cell Culture Models

In vitro models are useful in drug development because they can provide a cost-effective way to screen potential drug candidates before moving on to more expensive and time-consuming in vivo studies. However, traditional 2D cell culture models have limitations in replicating the complex in vivo microenvironment, which is where 3D cell culture models come in. 3D cell culture models better mimic the in vivo microenvironment and can offer improved in vivo relevancy, allowing for more accurate predictions of in vivo efficacy and toxicity. Additionally, 3D cell culture models can be used to confirm results of in vitro screening using 2D cells and for screening hits and lead compounds for potential toxic liabilities.

Overcoming Challenges

Assessing the distribution of biologicals for drug development is a costly and time-consuming process that typically requires the use of animal studies. Heterogeneous distribution of biologicals (especially antibody drugs) in tumor tissue has been recognized as a major issue for immunotherapy. Transport of biologicals into tissues is a complex process involving a combination of factors. The main mechanism by which biologicals distribute throughout tissue is convective transport. However, in solid tumors, functional lymphatic vessels are rare, leading to an increase in hydrostatic pressure, reducing the propensity of the convection gradient to drive macromolecules into the tumor. After permeation into the tissue compartments, distribution relies on a balance of diffusion, convection, and affinity to target antigens within the interstices and cell surfaces.

Our In Vitro Antibody Pharmacokinetics Assay overcomes these challenges by utilizing tumor spheroid models, grown to approximately 200 μm in diameter, and treating them with antibody therapeutics at various concentrations. The tumor spheroids are then fixed at specified time points, labeled with fluorescent secondary to label therapeutic antibody, and subjected to tissue clearing to render them transparent. High content confocal imaging is used to analyze the resultant images and assess the distance and quantity of Ab penetration into tumor spheroids. The assay can measure distribution curves, velocity curves, TD50 values, and concentration-time curves.

Data is analyzed using high content screening and markers such as DAPI. The assay can measure distribution curves, velocity curves, TD50 values, and concentration-time curves. The analysis involves assessing the distance and quantity of antibody penetration into tumor spheroids using confocal imaging.

This In Vitro Antibody Pharmacokinetics Assay offers a cost-effective and time-efficient alternative to animal studies for drug development. The assay can screen the relative differences in distribution of various biologicals, including antibody drug conjugates, antibody fragments, alternate domain antibodies, affibodies, and nanobodies. The assay can measure distribution curves, velocity curves, TD50 values, and concentration-time curves. The assay offers a cost-effective and time-saving alternative to animal studies for drug development. By utilizing 3D cell culture models and high content confocal imaging, the assay can provide more accurate predictions of in vivo efficacy and toxicity. To learn more about this assay, please reach out to a member of our team to get started today!

Drug discovery is a complex and challenging process that requires a significant investment of time, resources, and expertise. One of the key challenges in drug discovery is developing effective assays that can accurately predict the efficacy and safety of potential drug candidates. Liver fibrosis is a critical area of research, given the high prevalence of non-alcoholic fatty liver disease (NAFLD) and the lack of effective treatments for liver fibrosis. At Visikol, we offer a Liver Fibrosis Assay that uses 3D cell culture models incorporating a mixture of hepatocytes or hepatocyte-like cells with nonparenchymal cells (NPCs) to provide the greatest utility. The assay analyzes gene expression via qPCR, allowing for many genes of interest to be evaluated using a single sample. In this blog post, we will provide practical advice for researchers looking to use Visikol’s Liver Fibrosis Assay for drug discovery. We will cover tips and tricks for optimizing the assay, including best practices for plate cells, spheroid formation, treatment, endpoint assays, and analysis. We will also provide guidance on how to interpret the results of the assay and use them to make informed decisions about drug development.

Optimizing the Assay

Our Liver Fibrosis Assay is a powerful tool for drug discovery, but it requires careful optimization to achieve the best results. The first step in optimizing the assay is to carefully plate the cells. For generation of liver spheroids, 1500 cells/well (60% hepatocytes, 40% NPCs) are seeded into ULA U-bottom plates and maintained under standard culture conditions for 14 days to enable spheroid aggregation to a size of approximately 200 μm in diameter. Spheroids are then treated with test compounds, and if test compounds are intended to ameliorate rather than prevent fibrosis, test compounds will be added after induction of fibrosis. Following 1 h of pre-treatment (other timepoints available upon request), fibrosis is induced via addition of 100 ng/mL TGF-β for an additional 72 hours. Test article concentration is maintained through induction of fibrosis. It is important to maintain consistency in the number of cells plated, the plate format, and the quality controls used.

Spheroid formation is another critical step in the assay. The spheroids should be allowed to aggregate for at least 14 days before treatment to ensure that they are of the appropriate size and shape. The spheroids should be monitored regularly to ensure that they are healthy and viable.

Spheroid Treatment

Treatment of the spheroids is another critical step in the assay. The test compounds should be added at the appropriate concentration and timepoint to ensure that they are effective. The assay can be used to test compounds intended to prevent or treat fibrosis. The test compounds can be added after induction of fibrosis, and the assay can be used to assess the efficacy of anti-fibrotic agents.

Endpoint assays are critical for measuring the efficacy of drugs in liver fibrosis assays. The endpoint assays that can be used to measure the efficacy of drugs in liver fibrosis assays include qPCR, ELISA, and immunofluorescent labeling. The choice of endpoint assay will depend on the specific research question being addressed.

Interpreting the Results

Interpreting the results of the Liver Fibrosis Assay requires careful analysis of the data. The assay analyzes gene expression via qPCR, allowing for many genes of interest to be evaluated using a single sample. The results of the assay can be used to identify promising targets for modulation and amelioration of liver disease. Dose response curves and EC50 values for select genes of interest in response to anti-fibrotic agents are provided. The results of the assay can be used to make informed decisions about drug development, including which compounds to pursue and which to discard.

Why Work With Us?

Our Liver Fibrosis Assay uses 3D cell culture models that incorporate a mixture of hepatocytes or hepatocyte-like cells with nonparenchymal cells (NPCs) to provide the greatest utility. The assay analyzes gene expression via qPCR, allowing for many genes of interest to be evaluated using a single sample. We also offer custom drug discovery solutions to researchers who require a more customized approach to their drug discovery projects. Our quality control process that we have in place for all new cell and control compound lots ensure standardization of our liver assays. Additionally, we offer unparalleled techniques for evaluating compounds which modulate the processes along the continuum of NAFLD, including lipid deposition, inflammation, extracellular collagen deposition and fibrosis, and adjacent deleterious processes.

By following the tips and tricks outlined in this blog post, researchers can maximize the potential of the assay and make informed decisions about drug development. To learn more about, please reach out to a member of our team today!

In recent years, there has been a growing interest in the use of 3D cell culture models for drug discovery and development. These models have been shown to provide more relevant in vitro data compared to traditional 2D models, making them an attractive option for pharmaceutical companies looking to accelerate the drug discovery process. In this blog post, we will discuss the importance of 3D cell culture models in drug discovery and how they can provide more relevant in vitro data compared to traditional 2D models. We will highlight Visikol’s expertise in developing 3D cell culture models for drug screening and demonstrate how their High Content Screening services can help maximize in vitro relevancy. We will also discuss the benefits of using automation and robotics to accelerate the screening process while maintaining accuracy and reliability.

What Is High Content Screening?

High Content Screening (HCS) is a method of drug screening that allows for the assessment of multiple endpoints simultaneously at a cellular resolution, providing richer datasets than traditional assays. HCS utilizes High Content Imaging to interrogate and quantify cellular response to treatments, stimuli, or alterations in protein expression. The use of imaging-based endpoints allows for examination of the specific effect of compound treatments on specific sub-populations of cells, as well as providing access to more complex measurements than can be accomplished with traditional assay formats.

Why 3D Cell Culture Models?

3D cell culture models offer a more natural, tissue-mimicking method of cell growth for drug discovery applications compared to traditional 2D models. Cells grown as 3D models are more analogous to their existence in vivo, and may be co-cultured with other cells and cellular components that occur in their microenvironment to better recapitulate the disease. The technique in which cells are cultured (2D vs. 3D) can substantially alter the drug’s effect on the cells, and there are many examples in the literature
regarding the substantial differences between cells cultured in 2D vs 3D format.

Visikol recognizes the importance of 3D cell culture due to improved in vivo relevancy and relatively low-cost and works closely with clients to define the appropriate model for their specific research question or screening campaign. Visikol has an expert team of cell biologists with in-house capabilities to generate any models required and partnerships with major providers of 3D models when highly sophisticated models are required. Every assay provided in a 3D model format can be applied to monolayer models, and the team can quantify nearly any target using nearly any label.

Technology and High Content Screening

Automation, computerization, and robotics are used in the drug screening process to accelerate High Content Screening, and Visikol utilizes all of these methods to produce quick project turnaround. Visikol communicates progress with clients throughout the entire assay process and offers advice in assay design to ensure the best and most successful project. Visikol uses a purpose-built image processing pipeline to quickly parse through tens of thousands of images to obtain quantitative data, extracting cell counts, morphological features, colocalization of labels, and computing statistical comparisons between groups simultaneously.

The challenges in implementing 3D cell culture models in drug screening on a large scale include the cost and throughput requirements. The accuracy and reliability of drug screening can be improved when using automation and robotics. Visikol offers small-scale proof-of-concept work for custom projects to demonstrate their expertise and build clients’ confidence in their screening campaigns.

In conclusion, 3D cell culture models offer a more relevant and tissue-mimicking method of cell growth for drug discovery applications compared to traditional 2D models. Visikol’s expertise in developing 3D cell culture models for drug screening and their High Content Screening services can help maximize in vitro relevancy. The use of automation and robotics can accelerate the screening process while maintaining accuracy and reliability. Pharmaceutical companies, pharmaceutical scientists, biochemists, medicinal chemists, pharmacologists, and toxicologists can all benefit from the use of 3D cell culture models and High Content Screening in their drug discovery and development efforts. If you’re interested in learning more, reach out to a member of out team today!

Immunotherapy is a rapidly growing field in cancer treatment, with the aim of modulating tumor immunity to promote tumor-rejection. The development of immunotherapies is a complex process that requires the use of advanced technologies to evaluate the efficacy of compounds and therapeutic antibodies on immune cell infiltration or to screen immune cell populations for use in immunotherapy. In this blog post, we will explore how our in vitro immuno-oncology models can be used to accelerate the drug discovery and development process for immunotherapies. Our expertise lies in transforming tissues into actionable insights and bridging the gap between in vitro assays and in vivo results through the use of best-in-class cell culture models.

Advantages of Our In Vitro Immuno-Oncology Models

One of the key advantages of our in vitro immuno-oncology models is the ability to assess the effect of compounds and therapeutic antibodies on immune cell infiltration. Tumor-infiltrating immune cells are associated with better prognosis for cancer patients, and in vitro assays of immune cell infiltration can be used to evaluate the efficacy of immunotherapies designed to promote the immune cell response to tumor cells. Immunohistochemistry (IHC) is a typical analysis method for labeling T-cells in tumor tissue samples, but it is low throughput and costly. In vitro immuno-oncology models offer a more efficient and cost-effective alternative.

3D Cell Culture Models and Immuno-Oncology Models

Our in vitro immuno-oncology models also allow for the screening of immune cell populations for use in immunotherapy. The 3D cell culture models are more biologically relevant, and allow for proper assessment of immunotherapies designed to promote the immune cell response to tumor cells. The assay involves monitoring the interaction of therapeutics with immune cells in a 2D or 3D assay format. The protocol involves using 3D cell models, grown to approximately 200 μm in diameter, and seeding PBMCs at 4000 cells/well. The markers used for analysis include DAPI (total cell count), CD3, CD8, CD45RO, and other markers available on request.

These patented and proprietary technologies for tissue imaging, tissue processing, and image analysis are critical to the success of our in vitro immuno-oncology models. This approach allows for uniform labeling across thick tissues while preserving histological integrity, and the clearing process is reversible, allowing for further analyses. Specializing in many areas, we differentiate ourselves through our expertise in advanced imaging and image analysis, 3D cell culture models, and AI-enhanced digital pathology.

3D cell culture is a method of growing cells in a three-dimensional environment that more closely mimics the natural in vivo microenvironment. This allows for a more biologically relevant assessment of immunotherapies, as cells grown in 3D models can better replicate in vivo characteristics and interactions with other cells and cellular components. 3D cell culture models offer an excellent format for confirming results of in vitro screening using 2D cells, and for screening hits and lead compounds for potential toxic liabilities. However, determining when exactly to use a 3D cell culture model will depend on the specific research question but will also depend on the cost, throughput and in vivo relevancy of the 3D cell culture model.

Work With Us

Our advanced imaging and analysis technologies can provide important insights in the drug discovery process for immunotherapies. We offer high content screening for immune modulators, and have experience with immuno-oncology drug discovery and development. These tools ensure that drugs fail faster during the discovery process and that researchers can answer more complex research questions to inform their programs.

In vitro immuno-oncology models are an important tool in the drug discovery and development process for immunotherapies, and we are at the forefront of this field. If you are interested in learning more about our in vitro immuno-oncology models, please reach out to a member of our team to get started today!

Liver fibrosis is a serious condition that affects millions of people worldwide. It is a pathological overaccumulation of excess connective tissue resulting in scar formation, reduced organ function, and ultimately organ failure. The shift from appropriate wound healing to pathological fibrosis occurs as the rate of extracellular matrix deposition outstrips the rate of degradation. The causes of liver fibrosis can include chronic disease, autoimmune response, or long-term exposure to pollutants and toxins.

Symptoms of liver fibrosis may not be noticeable until the disease has progressed to cirrhosis. Diagnosis typically involves imaging tests, blood tests, and a liver biopsy. The prevalence of liver fibrosis is high, with nearly 45% of all deaths in the developed world attributed to chronic fibroproliferative diseases. It is more common in certain populations, such as those with chronic hepatitis B or C infections.

In Vitro Models

There are currently no approved treatments for liver fibrosis, but research is ongoing. In vitro models, such as the liver fibrosis assay offered by Visikol, are used to study the disease and potential treatments.

In vitro models are an essential tool for researchers studying liver fibrosis. These models allow researchers to study the disease in a controlled environment, without the need for animal models or human subjects. These models also allow researchers to evaluate multiple endpoints using a single sample, which can save time and resources.

One of the most significant advantages of in vitro models is the ability to use 3D cell culture models. These models incorporate a mixture of hepatocytes or hepatocyte-like cells with nonparenchymal cells (NPCs) to provide the greatest utility. 3D cell culture models offer a more accurate representation of the in vivo environment, allowing researchers to study the complex interactions between different cell types and the extracellular matrix that occur in vivo.

More on Visikol’s Liver Fibrosis Model

Visikol’s assay uses 3D cell culture models to study the disease and potential treatments. The assay analyzes gene expression via qPCR, allowing for many genes of interest to be evaluated using a single sample. The assay also offers basic and add-on endpoints, including qPCR, immunofluorescent labeling, ELISA, cytokine panels, plate reader cytotoxicity assay, and ATP assay. Dose response curves and EC50 values for select genes of interest in response to anti-fibrotic agents are provided.

The liver fibrosis assay offered by Visikol is an essential tool for researchers studying liver fibrosis. The assay provides highly-validated assays with consistency and quality control processes that are available for liver models. In vitro compound screening, gene expression analysis, immunolabeling and confocal imaging of liver models, preparation and analysis of tissue sections from animal or human tissues, and advanced image processing and classification of clinical specimens using machine learning are offered. Custom drug discovery solutions are available for researchers who require a more customized approach to their drug discovery projects.

Liver fibrosis is a serious condition that affects millions of people worldwide. In vitro models, such as the liver fibrosis assay offered by Visikol, are an essential tool for researchers studying the disease and potential treatments. The assay uses 3D cell culture models to provide a more accurate representation of the in vivo environment, allowing researchers to study the complex interactions between different cell types and the extracellular matrix that occur in vivo. The liver fibrosis assay offered by Visikol provides highly-validated assays with consistency and quality control processes that are available for liver models.

To learn more about the liver fibrosis assay offered by Visikol, please reach out to a member of our team today!

Cell culture labs across the world use a tremendous number of materials, from pipettes and media to plates, the latter arguably the most important. Plates are the backbone of in vitro assays and help play a part in study designs for screening or imaging.

In 3D cell culture, plate models are particularly important as the wells of plates need to be designed to allow cells to form into the spheroids, organoids and other 3D structures that are essential to drug discovery work.

There are a few key different plate designs that researchers can use when approaching a study:

“3D cell culture models may be generally classified into two principal categories based on method: 1) scaffold-based methods using hydrogels or structural scaffolds and 2) scaffold-free approaches using freely floating cell aggregates, typically referred to as spheroids. The choice of method depends principally on the nature of the cells themselves, but also on the goals and purpose of the 3D culture.” (Sigma)

Most major life science equipment manufacturers create and distribute their own 3D Cell culture plates. If not for individual sale, for the supplemental sale for their products (hoping to capture lasting revenue streams).

Ultra Low Attachment Plates

ULA plates, which stands for Ultra Low Attachment, is the leading design for 3D cell culture plates. ULA plates do not allow cells to adhere to the well itself, which subsequently forces the cells to form together into a 3D structure using gravity. These plates have proven to be easy to use and reproducible.

MatTek and BIOFLOAT^TM Plates

Our sister company MatTek has recently started to sell BIOFLOAT^TM plates to customers as a new product. The BIOFLOAT™ 96-well plate has unique anti-adhesive properties which making it a highly performing 3D cell culture plate:

“The polymeric coating enables a fast generation of 3D spheroids, which shortens your experimental timeline and prevents the formation of satellites and irregular aggregates. Choose between the ready-to-use 96-well plate and 384 well plates or DIY BIOFLOAT™ FLEX coating solution to modify a broad range of plastic and glass surfaces.” (Source)

The BIOFLOAT^TM plate focuses on time and quality – as the spheroid formation process is quick and consistent, allowing researchers to rapidly (and correctly) scale 3D cell culture studies. The plates are offered in 96-well and 384-well format, and samples are being offered currently.

The plates are currently listed on the MatTek website, and we encourage our customers to check out the BIOFLOAT^TM plate!

Liver fibrosis is a serious condition that affects millions of people worldwide. It is a pathological overaccumulation of excess connective tissue resulting in scar formation, reduced organ function, and ultimately organ failure. The shift from appropriate wound healing to pathological fibrosis occurs as the rate of extracellular matrix deposition outstrips the rate of degradation. The causes of liver fibrosis can include chronic disease, autoimmune response, or long-term exposure to pollutants and toxins.

More on Liver Fibrosis

Symptoms of liver fibrosis may not be noticeable until the disease has progressed to cirrhosis. Diagnosis typically involves imaging tests, blood tests, and a liver biopsy. The prevalence of liver fibrosis is high, with nearly 45% of all deaths in the developed world attributed to chronic fibroproliferative diseases. It is more common in certain populations, such as those with chronic hepatitis B or C infections.

There are currently no approved treatments for liver fibrosis, but research is ongoing. In vitro models, such as the liver fibrosis assay offered by Visikol, are used to study the disease and potential treatments.

Visikol’s Liver Fibrosis Assay

In vitro models are an essential tool for researchers studying liver fibrosis. These models allow researchers to study the disease in a controlled environment, without the need for animal models or human subjects. In vitro models also allow researchers to evaluate multiple endpoints using a single sample, which can save time and resources.

One of the most significant advantages of in vitro models is the ability to use 3D cell culture models. These models incorporate a mixture of hepatocytes or hepatocyte-like cells with nonparenchymal cells (NPCs) to provide the greatest utility. 3D cell culture models offer a more accurate representation of the in vivo environment, allowing researchers to study the complex interactions between different cell types and the extracellular matrix that occur in vivo.

Visikol’s 3D cell culture models to study the disease and potential treatments. The assay analyzes gene expression via qPCR, allowing for many genes of interest to be evaluated using a single sample. The assay also offers basic and add-on endpoints, including qPCR, immunofluorescent labeling, ELISA, cytokine panels, plate reader cytotoxicity assay, and ATP assay. Dose response curves and EC50 values for select genes of interest in response to anti-fibrotic agents are provided.

The assay provides highly-validated assays with consistency and quality control processes that are available for liver models. In vitro compound screening, gene expression analysis, immunolabeling and confocal imaging of liver models, preparation and analysis of tissue sections from animal or human tissues, and advanced image processing and classification of clinical specimens using machine learning are offered. Custom drug discovery solutions are available for researchers who require a more customized approach to their drug discovery projects.

Liver fibrosis is a serious condition that affects millions of people worldwide. In vitro models, such as Visikol’s liver fibrosis assay, are an essential tool for researchers studying the disease and potential treatments. If you’re interested in learning more, please reach out to a member of our team today!

Are you struggling to achieve the optimal 3D cell culture model? You are not alone in this, as many cell lines present unique challenges to successful spheroid formation. Culturing cells in three-dimensional (3D) environments is crucial for mimicking physiological conditions and studying cell behavior more accurately than traditional two-dimensional (2D) cultures; therefore, there is a push to better understand the 3D in vitro landscape. Let’s explore some of the cell lines that are often difficult to culture in 3D and the reasons behind their challenges:

Difficult Cell Lines

1. Primary Cells: Primary cells are directly isolated from tissues and have a limited lifespan in culture. They often struggle to maintain their functionality and viability in 3D systems over extended periods due to the absence of necessary growth factors and extracellular matrix components present in their natural microenvironment.
2. Stem Cells: Stem cells require specific niche factors and signaling cues for self-renewal and differentiation. Transitioning them to 3D culture systems can disrupt these critical signals, leading to altered differentiation potentials and reduced cell viability.
3. Slow-Growing Cells: Cells with inherently slow growth rates might face difficulties in forming spheroids or other 3D structures within a reasonable timeframe. These cells could struggle to establish proper cell-cell interactions and develop the necessary microenvironment for survival and growth.
4. Highly Adherent Cells: Cell lines that are tightly adherent to surfaces in 2D conditions might encounter challenges detaching and forming spheroids or aggregates in 3D cultures. Maintaining cell-cell contacts in a 3D environment without compromising viability can be complex for these cell types.
5. Cell Lines with Complex Signaling Requirements: Some cell lines rely heavily on intricate signaling pathways and interactions with surrounding cells and the extracellular matrix. Transferring them to 3D systems could disrupt these pathways, resulting in altered cell behavior and limited growth.
6. Oxygen and Nutrient Sensitivity: Certain cells are sensitive to oxygen and nutrient gradients that form within larger 3D structures. The limited diffusion of essential molecules in the interior of spheroids or organoids can lead to cell death and reduced growth.
7. Immortalized Cells: Immortalized cell lines often exhibit genetic mutations that enable continuous proliferation. These mutations might interfere with the cell’s ability to respond to the cues provided by 3D culture systems, affecting their growth and behavior.
8. Cell Lines with Complex Architecture: Cells that have complex architectures in vivo, such as neurons with long projections, might not recapitulate their natural morphology and functionality well in 3D systems. This can limit their utility in studying intricate cellular processes.
9. Tumor Cell Lines: While some tumor cell lines can form spheroids, their behavior in 3D culture might not accurately represent their behavior in vivo due to the lack of immune cells, stromal cells, and other components of the tumor microenvironment.
10. Cell Lines with Specialized Requirements: Some cell lines have unique growth requirements that are difficult to replicate in 3D culture systems. This could include specific growth factors, hormones, or culture conditions that are hard to mimic in vitro.

Researchers are continually working to optimize 3D culture conditions and develop techniques that address these challenges, enabling a broader range of cell lines to be cultured in more physiologically relevant environments.

We Can Help

If you are facing challenges in developing your 3D cell culture model, allow us to help! Visikol has a broad range of experience and expertise in 3D assay development and optimization. Reach out today to chat with our team of experts.

This particular blog post provides a comprehensive walk-through of the image analysis workflow utilized for The Antibody Penetration Assay. This assay is designed to measure the ability of therapeutic antibodies to penetrate tumor tissues, which is a critical factor in determining their effectiveness. The Antibody Penetration Assay is performed using 3D cell culture models, which closely mimic the in vivo environment of human tissue. These models are typically spheroids, which are composed of single or multiple cell types and have a more complex structure than traditional 2D cell cultures. The spheroids are treated with therapeutic antibodies at varying concentrations over time and then imaged using high-resolution microscopy.

3D Cell Model Analysis

The case below showcases the analysis of a 3D cell model, infused with D3 400 ng of Integrin. The spheroid was captured at 10X magnification (0.65 um/pixel), with a z-step size of 10um, using channels 405 and 488 to acquire the DAPI and antibody channels, respectively. Although the entire z-stack of the cell cluster is readily available, the current antibody penetration analysis is exclusively performed on the centermost slice of the 3D-image stack (as illustrated in Figures 1 and 2).

Determining the Boundary of the Spheroid

Before measuring the antibody channel, it is imperative to accurately determine the boundary of the spheroid. This is skillfully achieved by generating a mask of the spheroid through thresholding of the DAPI channel, as depicted in Figure 3. Once the boundary is determined, concentric rings traveling towards the center of the spheroid can be generated. These rings are binned by a 10um step size and applied to the antibody channel; the mean intensity is measured for each concentric ring (Figure 4).  By displaying the mean intensity as a function of depth into the spheroid (as exemplified in Figure 5), one can estimate an approximate penetration depth. For this low dose, it is observed that the majority of the signal is present at a depth of 20uM, tapering into ~50uM deep into the spheroid before leveling out.

Overall, the Antibody Penetration Assays a valuable tool for researchers and drug developers, as it provides a reliable method for evaluating the penetration of therapeutic antibodies into tissue. With the support of companies like Visikol, the APA has the potential to revolutionize the field of drug development and lead to more effective treatments for a wide range of diseases. If you have questions about The Antibody Penetration Assay, or specific questions pertaining to the image analysis workflow, reach out today!